Rapid Rx Quiz: Diabetes Drugs

Mary L. Windle, PharmD

Disclosures

May 13, 2022

Current ADA guidelines indicate that clinicians should prescribe a medication with demonstrated cardiovascular benefit for patients with ASCVD who are on metformin and are unable to achieve the A1c target. Specifically, they recommend a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist because several of these drugs have gained approval to reduce the risk for death in adults with T2D and cardiovascular disease. Factors informing the selection process may include considering whether the patient prefers oral or injectable administration, whether weight loss is a goal, and adverse effects and contraindications.

Learn more about SGLT2 inhibitors in T2D.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....